Future clinical studies on AD patients, treated with istradefylline or with other old and new A2A antagonists, will be required, and the role of A2A receptor as biomarker may help to optimize patients’ enrollment and assumption protocol and dosages. The gene discussed is IGKV2D-29; the disease is Alzheimer disease.